In vivo Enhancement in Bioavailability of Atazanavir in the Presence of Proton‐Pump Inhibitors using Mesoporous Materials

Self-Assembly Mechanism of Folate-Templated Mesoporous Silica

“…We expected that further supramolecular materials with new properties will be derived through the encapsulation of pterin derivatives, and their investigation in pharmaceutical applications is already under way. 31,32 ■ ASSOCIATED CONTENT…”

Amorphous Solid Dispersions

“…22.6a, b, c). In accordance with nano-confinement effects of drugs within cylindrical channels, the smaller pore size material (in the case NFM-1) results in the highest enhancement in apparent solubility (Xia et al 2012b). To investigate further the extent of the solubility enhancement using mesoporous silica carriers, dissolution curves were obtained for NFM-1-ATV at different particles-to-SIF ratios: 20, 40, 80 and 160 mg L −1 (Fig.…”

“…Vallet-Regi et al made this connection in 2001, and pioneered the field of pharmaceutical drug release using mesoporous materials (Yongde and Mokaya 2003;. As functional excipients for the pharmaceutical industry, ordered mesoporous silica particles have been shown in vitro and in vivo to: load large pay loads of single or multiple active molecules ; tailor the pharmacokinetic release profiles through diffusion or other mechanisms (Brohede et al 2008); target the release of pharmaceutical products to specific cell types ; increase the bioavailability of pH-sensitive drug candidates (Xia et al 2012a); enhance the solubility of hydrophobic pharmaceutical actives with high partition constants (van Speybroeck et al 2010); act as adjuvants in immunotherapies; act as a diagnostic and theranostic particles ; and enhance the growth of apatite layers in tissue generation and bone implants (Wu and Chang 2012).…”

“…The solid remaining will typically be composed of the mesoporous silica loaded with drugs, with a small fraction of drug remaining outside the pores and on the particle surface. Particularly for poorly soluble compounds, this method results in the formation of drug crystals outside of the pores (Xia et al 2012a). Drug remaining on the surface will possess different dissolution behaviour than that loaded within the pores (van Speybroeck et al 2010).…”

Non-absorbable mesoporous silica for the development of protein sequestration therapies

“…[12] The enhancement of apparent solubility of pharmaceutical compounds in order to improve their eventual bioavailability and general pharmacokinetic properties is emerging as an area where MS can provide tangible industrial and clinical benefit. [13,14,15] In another instance, the mild but significant vaccine adjuvant effects observed further highlight mesoporous materials as an untapped area for vaccine discovery moving forward. [16,17] The administration of pharmaceutical drugs or therapeutic agents via the gastro intestinal tract (GIT) offers numerous advantages over intravenous or dermal routes, in particular patient compliance.…”